Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 5/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.45 |
| ▸ | ESRRG | P62508 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520946 | 1.00 | SLC18A3 (0.52) | SLC18A3TLR9TLR8TLR7ESRRG | |
| SCHEMBL22805197 | 0.84 | SLC18A3 (0.62) | SLC18A3TLR9TLR8TLR7DRD2 | |
| SCHEMBL27579835 | 0.84 | DRD2 (0.62) | SLC18A3DRD2 | |
| SCHEMBL22805198 | 0.84 | SLC18A3 (0.62) | SLC18A3TLR9TLR8TLR7DRD2 | |
| SCHEMBL8572351 | 0.84 | SLC18A3 (0.56) | SLC18A3TLR9TLR8TLR7DRD2 | |
| SCHEMBL520725 | 0.83 | SLC18A3 (0.55) | SLC18A3TLR9TLR8TLR7 | |
| SCHEMBL520726 | 0.83 | SLC18A3 (0.55) | SLC18A3TLR9TLR8TLR7 | |
| SCHEMBL17630951 | 0.81 | SLC18A3 (0.48) | SLC18A3TLR9TLR8TLR7DRD2 | |
| SCHEMBL9952448 | 0.81 | KMT2A (0.52) | SLC18A3TLR9TLR8TLR7 | |
| SCHEMBL520767 | 0.80 | NPM1 (0.49) | SLC18A3TLR9TLR8TLR7DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | SLC18A3 4672/4885TLR9 1729/4885TLR8 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.